Silver Spring, Maryland–(ENEWSPF)–December 17, 2015. The U.S. Food and Drug Administration yesterday approved Basaglar (insulin glargine injection), a long-acting human insulin analog to improve glycemic control in adult and pediatric patients with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus.
